Detection of Metallo-Beta Lactamases Among Carbapenem-Resistant Pseudomonas aeruginosa

Detection of Metallo-Beta Lactamases Among Carbapenem-Resistant Pseudomonas aeruginosa

BACKGROUND Carbapenems are important drugs used for the treatment of Pseudomonas aeruginosa infections, however metallo-β-lactamases (MBL) are able to efficiently hydrolyze these classes of drugs. Immediate detection of the MBL-producing P. aeruginosa is necessary in order to accurately treat infections caused by this organism. OBJECTIVES To determine the prevalence of MBL producing P. aerugi...

detection of metallo-beta lactamases among carbapenem-resistant pseudomonas aeruginosa

conclusions epidemiological and regional evaluation of mbl-producing p. aeruginosa through simple and inexpensive methods should be considered for effective treatment of carbapenem-resistant p. aeruginosa infections. results amongst all the p. aeruginosa isolates, 58.7% were resistant to imipenem while 31.8%, 13.5% and 74.4% were resistant to meropenem, doripenem and ertapenem, respectively. am...

Phenotypic and Genotypic Detection of Metallo-Beta-Lactamases in Carbapenem Resistant Acinetobacter baumannii

Metallo‐beta‐lactamases among imipenem‐resistant Pseudomonas aeruginosa in a brazilian university hospital

INTRODUCTION Imipenem-resistant Pseudomonas aeruginosa resulting from metallo-β-lactamases has been reported to be an important cause of nosocomial infection and is a critical therapeutic problem worldwide, especially in the case of bacteremia. OBJECTIVES To determine the frequency of metallo-β-lactamases among imipenem-resistant Pseudomonas aeruginosa isolates and to compare methods of pheno...

IMPs, VIMs and SPMs: the diversity of metallo-beta-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in a Brazilian hospital.

Pseudomonas aeruginosa isolates (n=183), collected from bacteraemic patients hospitalised in Sao Paulo Hospital (Brazil) during 2000-2001, were screened for susceptibility to antimicrobial agents. The polymyxins were the most active compounds (100% susceptibility), followed by amikacin and cefepime (59.0%), meropenem (57.4%), and imipenem and gentamicin (55.2%). Imipenem-resistant isolates were...